article Open AccessTop 1% cited

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology · 2015 · Vol. 173(6) · pp. 1387–1399

C. Paul✉(Hôpital Larrey)Jennifer Clay Cather(Dallas Nephrology Associates)Melinda Gooderham(SKiN Health)Yves Poulin(Centre de Recherche Dermatologique du Québec Métropolitain)Ulrich MrowietzC. Ferrandiz(Universitat Autònoma de Barcelona)J. Crowley(Bakersfield College)ChiaChi Hu(Bristol-Myers Squibb (Switzerland))R.M. Stevens(Bristol-Myers Squibb (Switzerland))Kara N. Shah(Bristol-Myers Squibb (Switzerland))R. M. Day(Bristol-Myers Squibb (Switzerland))Giampiero Girolomoni(University of Verona)A.B. Gottlieb(Tufts Medical Center)

View via DOI Full-text PDF

Abstract

Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52 weeks.

Psoriasis: Treatment and Pathogenesis Asthma and respiratory diseases Pregnancy and Medication ImpactApremilastMedicinePsoriasisPlaceboAdverse effectPsoriasis Area and Severity IndexInternal medicineDermatology Life Quality IndexNauseaRandomized controlled trial

MeSH terms

Administration, OralAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalChronic DiseaseDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedPsoriasisThalidomideTreatment Outcome